Here’s the full picture. The data is sobering.
## DXC Technology: Market Analysis
### Stock Price — 5-Year Collapse
The trajectory is consistent destruction of value: from a 2018 average of ~$80 (peak $93), the stock fell 35% that year, another 28% in 2019, another 30% in 2020. A brief recovery of 25% in 2021 was the last positive year.
From there: -17.7% in 2022, -13.7% in 2023. Into 2024 it was trading around $22–23. The 52-week high was $16.45 in July 2025 — already half of where it was in 2023. The 52-week low hit $7.90 in May 2026. YTD return as of mid-2026: -43.89%.
From $93 peak to ~$8–9 today. That is roughly a 90% destruction of equity value over 8 years.
The consensus from 8 analysts is “Hold.” Average price target: $11.43. BMO Capital lowered its target to $10 from $17, keeping Market Perform. Nobody is bullish. “Hold” at $8–9 is essentially “we don’t know how much further this falls.”
### Revenue — Uninterrupted Decline
Annual revenue of approximately $13.7 billion in FY2024, a decline of over two billion dollars from FY2022.
FY2025 came in at $12.87 billion, down 5.82%. Revenue in the last twelve months (to December 2025) is $12.68 billion, down 3.09% year-over-year.
The most recent quarter: Q4 FY2026 total revenue of $3.13 billion, down 1.2% year-over-year on a reported basis — but down 6.6% on an organic basis. The nominal improvement in reported numbers is forex noise, not operational recovery.
The full organic picture over FY2025: Q1: -4.4%, Q2: -5.6%, Q3: -4.2%, Q4: -4.2%. Full year organic decline: -4.6%. The GIS segment is worse: GIS organic revenue growth across FY2025 was Q1: -9.3%, Q2: -9.6%, Q3: -7.8%, Q4: -6.0% — full year -8.2%.
This is not a one-quarter blip. It is a structural, multi-year revenue haemorrhage.
### “No New Business” — The Book-to-Bill Problem
This is the core issue you’ve identified. In Q1 FY2025, the book-to-bill ratio was 0.77x — compared to 0.89x in Q1 FY2024. A book-to-bill below 1.0 means the company is booking less revenue than it is recognising — i.e., the backlog is shrinking. Consistently below 1.0 is a company consuming itself.
Q2 FY2025 overall book-to-bill: 0.90x. GIS specifically: 0.71x. GIS — their largest segment — was winning less than 71 cents of new work for every dollar of revenue recognised. That is accelerated decline built into future numbers.
The more recent figures look marginally better: Q2 FY2026 trailing twelve-month book-to-bill: 1.15x, with GIS at 1.08x on TTM basis. But context matters — Q4 FY2026 bookings gave a book-to-bill of 1.07x , and organic revenue still fell 6.6% that quarter. Booking more doesn’t reverse the run-off from long-term contracts signed years ago that are now expiring or being reduced.
DXC has made zero acquisitions since November 2019. Over the last five years, the average number of acquisitions per year is zero. There is no inorganic growth play. They are entirely dependent on winning organic new business — which they have been structurally failing to do for years.
### Profitability and Cash — The Complicating Factor
DXC is not going to zero next quarter. Full fiscal year 2026 free cash flow was $713 million, up 3.8% year-over-year. The company repurchased $250 million of shares in FY2026.
Gross margin remained relatively stable at 24.09%, and adjusted EBIT margins are being maintained.
But: GAAP EBIT in Q4 FY2026 was negative — $(39) million, a margin of -1.2%. The gap between non-GAAP “adjusted” figures and GAAP reality has been persistently large due to restructuring charges, amortisation, and pension adjustments. The company has been in near-permanent “restructuring” mode for years.
ROIC is below WACC. The company is destroying economic value — it is worth less each year as an operating entity than the capital tied up in it.
### Can It Survive?
Survival as a listed independent company: questionable beyond 3–5 years without a revenue inflection that has not yet materialised.
The structural problem is this: DXC is a legacy IT outsourcer. Its model — large long-term managed services contracts, rates × hours pricing — is being eroded by cloud migration (clients bring workloads in-house or to hyperscalers), offshore competition (TCS, Infosys, Wipro at lower cost), and now AI automation eating into the billable hour. The CEO acknowledges this directly: “The era of rates times hours is ending.” True. The question is whether DXC can pivot to something else before the existing base runs off.
FY2027 guidance anticipates further revenue decline but margin stability, with AI-driven offerings cited as future support. Every IT services company is saying the same thing about AI. DXC is late to that narrative and has no obvious differentiation.
The most likely exit is acquisition. There have been renewed reports of private equity interest, and in late 2022 a Baring Private Equity Asia takeover was rumoured but fell through. At ~$4.1 billion market cap generating $700M+ of free cash flow annually, the FCF yield is enormous — it is obviously a PE target. The asset would be stripped, carved up, and the cash flow harvested while the workforce is cut.
A shareholder lawsuit investigation was launched in June 2026 , which adds legal distraction at a strategically vulnerable moment.
### Summary Assessment
| Dimension |
Verdict |
| Stock price (5-year) |
-90% from peak, -44% YTD 2026 |
| Revenue trend |
Organic decline ~4–9% every year since FY2020 |
| New business |
Book-to-bill mostly <1.0 for years; recent marginal improvement |
| Inorganic growth |
Zero acquisitions since 2019 |
| Cash generation |
Strong (~$700M FCF) — the one positive |
| Economic value creation |
Negative — ROIC below WACC |
| Competitive position |
Structural moat deterioration, no durable advantage |
| Survival as independent |
Uncertain — more likely PE acquisition than organic recovery |
The cash generation is real and buys time. It also makes the company attractive to a buyer who can cut costs more aggressively than management has been willing to. The narrative around AI and “Xponential AI” and “OASIS” is exactly what a company in distress says. What matters is whether bookings translate into arrested revenue decline — and the gap between book-to-bill improving and organic revenue still falling 6.6% in Q4 FY2026 tells you there is a significant lag at best, a structural impossibility at worst.
The company is not dying this year. It is in managed, prolonged decline, and the probability of meaningful independent recovery is low.
Confidence: High on the factual picture; moderate on the 3–5 year outcome (acquisition vs. slow suffocation are both plausible; a genuine revenue turnaround is the low-probability scenario).